NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Clinical trial NCT06379217 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06379217
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-29
- Primary completion
- 2026-08-31
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.